Compare Stocks: CHUC, TRSSF, LFCR, and NRXP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHUC Charlie's	$0.18 -2.8%	$0.20	$0.15 ▼ $0.38	$50.50M	1.35	83,788 shs	78,396 shs
LFCR Lifecore Biomedical	$4.09 -5.1%	$4.59	$3.63 ▼ $8.98	$163.15M	1.08	119,580 shs	264,784 shs
NRXP NRx Pharmaceuticals	$3.37 -2.9%	$3.65	$1.62 ▼ $5.05	$150.24M	2.19	718,039 shs	520,173 shs
TRSSF TerrAscend	$0.68 -2.0%	$0.58	$1.62 ▼ $1.80	$170.36M	2.89	131,026 shs	175,947 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHUC Charlie's	-2.78%	-5.41%	-10.90%	-27.84%	-44.34%
LFCR Lifecore Biomedical	-5.10%	-13.71%	-12.23%	-27.61%	-43.66%
NRXP NRx Pharmaceuticals	-2.88%	-2.60%	+0.60%	-14.03%	+6.98%
TRSSF TerrAscend	-1.97%	+8.18%	+29.76%	-6.09%	-13.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHUC Charlie's	$0.18 -2.8%	$0.20	$0.15 ▼ $0.38	$50.50M	1.35	83,788 shs	78,396 shs
LFCR Lifecore Biomedical	$4.09 -5.1%	$4.59	$3.63 ▼ $8.98	$163.15M	1.08	119,580 shs	264,784 shs
NRXP NRx Pharmaceuticals	$3.37 -2.9%	$3.65	$1.62 ▼ $5.05	$150.24M	2.19	718,039 shs	520,173 shs
TRSSF TerrAscend	$0.68 -2.0%	$0.58	$1.62 ▼ $1.80	$170.36M	2.89	131,026 shs	175,947 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHUC Charlie's	-2.78%	-5.41%	-10.90%	-27.84%	-44.34%
LFCR Lifecore Biomedical	-5.10%	-13.71%	-12.23%	-27.61%	-43.66%
NRXP NRx Pharmaceuticals	-2.88%	-2.60%	+0.60%	-14.03%	+6.98%
TRSSF TerrAscend	-1.97%	+8.18%	+29.76%	-6.09%	-13.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHUC Charlie's	0.00	N/A	N/A	N/A
LFCR Lifecore Biomedical	2.00	Hold	$6.50	58.92% Upside
NRXP NRx Pharmaceuticals	2.43	Hold	$34.50	923.74% Upside
TRSSF TerrAscend	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CHUC, TRSSF, LFCR, and NRXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	NRXP NRx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	NRXP NRx Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/25/2026	LFCR Lifecore Biomedical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/10/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$10.00
8/5/2026	NRXP NRx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/4/2026	LFCR Lifecore Biomedical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	LFCR Lifecore Biomedical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
6/30/2026	LFCR Lifecore Biomedical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHUC Charlie's	$20.92M	2.35	$0.02 per share	9.81	$0.01 per share	17.50
LFCR Lifecore Biomedical	$128.87M	1.20	N/A	N/A	$0.42 per share	9.74
NRXP NRx Pharmaceuticals	$1.23M	118.63	N/A	N/A	($0.54) per share	-6.24
TRSSF TerrAscend	$247.83M	0.69	N/A	N/A	$1.28 per share	0.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHUC Charlie's	$4.50M	-$0.01	N/A	N/A	N/A	-7.47%	-63.51%	-16.47%	N/A
LFCR Lifecore Biomedical	N/A	-$1.07	N/A	N/A	N/A	-29.93%	N/A	-16.16%	10/2/2026 (Estimated)
NRXP NRx Pharmaceuticals	-$28.62M	-$0.55	N/A	N/A	N/A	-691.81%	N/A	-63.92%	11/13/2026 (Estimated)
TRSSF TerrAscend	-$329.91M	-$0.14	N/A	N/A	N/A	-125.03%	-6.66%	-3.07%	N/A

Latest CHUC, TRSSF, LFCR, and NRXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	CHUC Charlie's	N/A	-$0.01	N/A	-$0.01	N/A	$3.80 million
8/17/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.1067	-$0.44	-$0.3333	-$0.44	$1.33 million	$1.10 million
8/5/2026	Q2 2026	LFCR Lifecore Biomedical	-$0.19	-$0.19	N/A	-$0.19	$34.18 million	$34.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHUC Charlie's	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRSSF TerrAscend	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHUC Charlie's	0.69	1.65	0.40
LFCR Lifecore Biomedical	N/A	3.87	2.69
NRXP NRx Pharmaceuticals	N/A	0.86	0.86
TRSSF TerrAscend	0.55	0.73	0.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHUC Charlie's	7.80%
LFCR Lifecore Biomedical	83.36%
NRXP NRx Pharmaceuticals	4.27%
TRSSF TerrAscend	0.04%

Insider Ownership

Company	Insider Ownership
CHUC Charlie's	20.30%
LFCR Lifecore Biomedical	32.68%
NRXP NRx Pharmaceuticals	6.40%
TRSSF TerrAscend	32.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHUC Charlie's	40	280.55 million	223.60 million	Not Optionable
LFCR Lifecore Biomedical	690	37.85 million	25.48 million	Optionable
NRXP NRx Pharmaceuticals	2	43.30 million	40.53 million	Optionable
TRSSF TerrAscend	740	251.86 million	168.93 million	Not Optionable

CHUC, TRSSF, LFCR, and NRXP Headlines

Recent News About These Companies

TerrAscend Renews $10 Million Share Buyback to Boost Investor Value

August 20, 2026 | tipranks.com

TerrAscend Strengthens Balance Sheet With New Convertible Debentures

June 25, 2026 | tipranks.com

TerrAscend Shareholders Back Board Slate and Incentive Plans

June 15, 2026 | tipranks.com

TerrAscend Appoints Eric Jackson as New CFO

April 16, 2026 | tipranks.com

TerrAscend Sets March Date to Report 2025 Results and Hold Earnings Call

February 10, 2026 | tipranks.com

TerrAscend expands New Jersey footprint with Union Chill deal

December 30, 2025 | tipranks.com

TerrAscend Renews $10 Million Share Repurchase Program

August 20, 2025 | tipranks.com

TerrAscend Corp. (TSNDF) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

TerrAscend Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

TerrAscend Corp Expands Loan for Growth Initiatives

July 9, 2025 | tipranks.com

TerrAscend Corp. (TSNDF) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

TerrAscend Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

TerrAscend Corp. (TSNDF) Q4 2024 Earnings Call Transcript

March 6, 2025 | seekingalpha.com

TerrAscend Reports Steady Q4 Growth Amid Market Challenges

January 31, 2025 | tipranks.com

TerrAscend Corp Promotes Lynn Gefen to Key Role

November 26, 2024 | tipranks.com

Cannabis Stocks Plunged After Florida Legalization Failed: Rational Reaction Or Market Overreach?

November 9, 2024 | benzinga.com

TerrAscend Expands Footprint Despite Q3 Losses, Can A Move To Ohio Turn The Tide?

November 6, 2024 | benzinga.com

TerrAscend Corp Stock (OTC:TRSSF), Short Interest Report

October 21, 2023 | benzinga.com

Which Is the Better Cannabis Growth Stock for You: Cresco Labs or TerrAscend?

October 19, 2023 | msn.com

EXCLUSIVE: Why TerrAscend's Success Doesn't Rely On Federal Cannabis Reform

September 28, 2023 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHUC, TRSSF, LFCR, and NRXP Company Descriptions

Charlie's OTCMKTS:CHUC

$0.18 -0.01 (-2.78%)

As of 09/9/2026 03:51 PM Eastern

Charlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.

Lifecore Biomedical NASDAQ:LFCR

$4.09 -0.22 (-5.10%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$4.08 -0.01 (-0.24%)

As of 09/9/2026 07:30 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

NRx Pharmaceuticals NASDAQ:NRXP

$3.37 -0.10 (-2.88%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$3.32 -0.05 (-1.48%)

As of 04:46 AM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

TerrAscend OTCMKTS:TRSSF

$0.68 -0.01 (-1.97%)

As of 09/8/2026

TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis-infused artisan edibles. It also operates retail dispensaries under the Apothecarium brand name in California, Pennsylvania, and New Jersey. In addition, the company owns various synergistic businesses under Gage Growth, Pinnacle, TerrAscend NJ, Ilera Healthcare, HMS Health and HMS Processing, Valhalla Confections, State Flower, Arise Bioscience Inc., and TerrAscend Canada brands. It serves medical and legal adult-use markets. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHUC, TRSSF, LFCR, and NRXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHUC, TRSSF, LFCR, and NRXP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHUC, TRSSF, LFCR, and NRXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHUC, TRSSF, LFCR, and NRXP Company Descriptions

Charlie's OTCMKTS:CHUC

Lifecore Biomedical NASDAQ:LFCR

NRx Pharmaceuticals NASDAQ:NRXP

TerrAscend OTCMKTS:TRSSF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHUC, TRSSF, LFCR, and NRXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHUC, TRSSF, LFCR, and NRXP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHUC, TRSSF, LFCR, and NRXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHUC, TRSSF, LFCR, and NRXP Company Descriptions

Charlie's OTCMKTS:CHUC

Lifecore Biomedical NASDAQ:LFCR

NRx Pharmaceuticals NASDAQ:NRXP

TerrAscend OTCMKTS:TRSSF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools